Imagotype
PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with <i>RAS/BRAF</i> wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to <i>MET</i> amplification (<i>MET</i>amp). | Publicación